Skip to main content
Equibles

EGTX · Egetis Therapeutics AB (publ) · Financials

Use EGTX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research EGTX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
9.5400 SEK -0.0200 (-0.21%) At close · Oct 7
Rebalance outlook locked
Market Cap
4.44B SEK
Shares
464.97M

Income-statement, balance-sheet and cash-flow figures read from the company's own published financial reports.

Pull these statements through the financial statements API or MCP →

Browse captured authority reports and their original financial labels

Revenue
62.4M +35.4%
FY2025 Revenue FY2020–FY2025
Net Income
-342.5M +0.3%
FY2025 Net Income FY2020–FY2025
Gross Margin
19.87% -55pp
FY2025 Gross Margin FY2023–FY2025
Operating Margin
-544.71% +169.8pp
FY2025 Operating Margin FY2020–FY2025
Operating Cash Flow
-267M -17.2%
FY2025 Operating Cash Flow FY2020–FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics
Annual Quarterly
Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020
SEK 62.4M 46.1M 57.6M 22.6M 38.2M 40.66M
SEK 50M 11.6M 11M — — —
SEK 12.4M 34.5M 46.6M — — —
SEK 158.3M 146.2M 194M — — —
SEK 97.3M 109.7M 86.6M — — —
SEK 103.7M 105.6M 86.2M — — —
SEK -339.9M -329.4M -324.8M -198.1M -105.7M -177.3M
SEK 22.7M 25.9M 4.2M 700K 200K 888K
SEK -342.1M -343.2M -326.8M -193.8M -104.5M -178.02M
SEK 400K 300K 100K 0 0 0
SEK -342.5M -343.6M -326.9M -193.8M -104.5M -178.02M
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2024–FY2025: 1.5M in buybacks.

Debt Profile

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Reported debt balances

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balanceAs ofAmountSource
Current borrowings, including current portion of noncurrent borrowings 2025-12-31 SEK 31,500,000 ESEF Annual Report filed 2026-03-24
Noncurrent long-term borrowings 2025-12-31 SEK 45,000,000 ESEF Annual Report filed 2026-03-24
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.

Covenants

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

Loans, facilities and notes

The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.